Exact Mass: 329.29297840000004

Exact Mass Matches: 329.29297840000004

Found 106 metabolites which its exact mass value is equals to given mass value 329.29297840000004, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Homoormosanine

(7alpha,9alpha,11alpha,16beta,18beta)-Homoormosanine

C21H35N3 (329.28308300000003)


   

Dihydroceramide

N-[(2S,3R)-1,3-Dihydroxyoctadecan-2-yl]formamide

C19H39NO3 (329.29297840000004)


Dihydroceramide is an intermediate in sphingolipid metabolism. Dihydroceramide is the third to last step in the synthesis of beta-D-Galactosyl-1,4-beta-D glucosylceramide and is converted from sphinganine via the enzyme acyl-CoA-dependent ceramide synthase (EC 2.3.1.24). It is then converted to N-acylsphingosine via the enzyme fatty acid desaturase (EC 1.14.-.-). [HMDB] Dihydroceramide is an intermediate in sphingolipid metabolism. Dihydroceramide is the third to last step in the synthesis of beta-D-Galactosyl-1,4-beta-D glucosylceramide and is converted from sphinganine via the enzyme acyl-CoA-dependent ceramide synthase (EC 2.3.1.24). It is then converted to N-acylsphingosine via the enzyme fatty acid desaturase (EC 1.14.-.-).

   

Palmitoyl Serinol

N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-hexadecanamide

C19H39NO3 (329.29297840000004)


2-Palmitoyl glycerol (2-PG) has been isolated along with the potent endocannabinoid 2-arachidonoyl glycerol (2-AG) from various tissues.1 Although 2-PG displays no intrinsic agonist activity on CB1 or CB2 receptors, it does potentiate the ability of 2-AG to inhibit adenylyl cyclase. 2-PG also potentiates the analgesic, hypokinetic, and anxiolytic effects of 2-AG in mice. This ?entourage? effect has been attributed to the ability of compounds such as 2-PG to inhibit reuptake and/or compete with the active endocannabinoids for access to inactivating enzymes such as FAAH and monoglyceride lipase.2,3 Palmitoyl serinol is a stable analog of 2-PG bearing an amide linkage in place of the labile glyceryl ester. This has the potential to enhance its ?entourage? activities as a result of a prolonged in vivo half-life. Palmitoyl serinol is also an analog of C-16 ceramide. Incubation of neuroblastoma cells with palmitoyl serinol causes apoptosis with an IC50 of approximately 80 ?M. [HMDB] 2-Palmitoyl glycerol (2-PG) has been isolated along with the potent endocannabinoid 2-arachidonoyl glycerol (2-AG) from various tissues.1 Although 2-PG displays no intrinsic agonist activity on CB1 or CB2 receptors, it does potentiate the ability of 2-AG to inhibit adenylyl cyclase. 2-PG also potentiates the analgesic, hypokinetic, and anxiolytic effects of 2-AG in mice. This "entourage" effect has been attributed to the ability of compounds such as 2-PG to inhibit reuptake and/or compete with the active endocannabinoids for access to inactivating enzymes such as FAAH and monoglyceride lipase.2,3 Palmitoyl serinol is a stable analog of 2-PG bearing an amide linkage in place of the labile glyceryl ester. This has the potential to enhance its "entourage" activities as a result of a prolonged in vivo half-life. Palmitoyl serinol is also an analog of C-16 ceramide. Incubation of neuroblastoma cells with palmitoyl serinol causes apoptosis with an IC50 of approximately 80 µM.

   

4,8 Dimethylnonanoyl carnitine

3-[(4,8-dimethylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


4,8 dimethylnonanoyl carnitine is an intermediate in phytanic and pristanic acid metabolism. Both phytanic acid and pristanic acid are initially oxidized in peroxisomes to 4,8-dimethylnonanoyl-CoA, which is then converted to to 4,8-dimethylnonanoyl carnitine (presumably by peroxisomal carnitine octanoyltransferase), and exported to the mitochondrion. After transport across the mitochondrial membrane and transfer of the acylgroup to coenzyme A, further oxidation to 2,6-dimethylheptanoyl-CoA occurs (PMID: 9469587). 4,8 dimethylnonanoyl carnitine is not a substrate for carnitine acetyltransferase, another acyltransferase localized in peroxisomes, which catalyzes the formation of carnitine esters of the other products of pristanic acid beta-oxidation, namely acetyl-CoA and propionyl-CoA. (PMID: 10486279). Earlier studies have shown that pristanic acid undergoes three cycles of beta-oxidation in peroxisomes to produce 4,8-dimethylnonanoyl-CoA (DMN-CoA) which is then transported to the mitochondria for full oxidation to CO(2) and H(2)O. In principle, this can be done via two different mechanisms in which DMN-CoA is either converted into the corresponding carnitine ester or hydrolyzed to 4,8-dimethylnonanoic acid plus CoASH.(PMID: 11785945). Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) and pristanic acid (2,6,10,14-tetramethylpentadecanoic acid) are branched-chain fatty acids that are constituents of the human diet. As phytanic acid possesses a beta-methyl group, it cannot be degraded by beta-oxidation. Instead, phytanic acid is first degraded by alpha-oxidation, yielding pristanic acid, which is subsequently degraded by beta-oxidation. Phytanic acid alpha-oxidation is thought to occur partly, and pristanic acid beta-oxidation exclusively, in peroxisomes. Accumulation of phytanic acid and pristanic acid is found in blood and tissues of patients affected with generalized peroxisomal disorders. [HMDB] 4,8 dimethylnonanoyl carnitine is an intermediate in phytanic and pristanic acid metabolism. Both phytanic acid and pristanic acid are initially oxidized in peroxisomes to 4,8-dimethylnonanoyl-CoA, which is then converted to to 4,8-dimethylnonanoyl carnitine (presumably by peroxisomal carnitine octanoyltransferase), and exported to the mitochondrion. After transport across the mitochondrial membrane and transfer of the acylgroup to coenzyme A, further oxidation to 2,6-dimethylheptanoyl-CoA occurs (PMID: 9469587). 4,8 dimethylnonanoyl carnitine is not a substrate for carnitine acetyltransferase, another acyltransferase localized in peroxisomes, which catalyzes the formation of carnitine esters of the other products of pristanic acid beta-oxidation, namely acetyl-CoA and propionyl-CoA. (PMID: 10486279). Earlier studies have shown that pristanic acid undergoes three cycles of beta-oxidation in peroxisomes to produce 4,8-dimethylnonanoyl-CoA (DMN-CoA) which is then transported to the mitochondria for full oxidation to CO(2) and H(2)O. In principle, this can be done via two different mechanisms in which DMN-CoA is either converted into the corresponding carnitine ester or hydrolyzed to 4,8-dimethylnonanoic acid plus CoASH.(PMID: 11785945). Phytanic acid (3,7,11,15-tetramethylhexadecanoic acid) and pristanic acid (2,6,10,14-tetramethylpentadecanoic acid) are branched-chain fatty acids that are constituents of the human diet. As phytanic acid possesses a beta-methyl group, it cannot be degraded by beta-oxidation. Instead, phytanic acid is first degraded by alpha-oxidation, yielding pristanic acid, which is subsequently degraded by beta-oxidation. Phytanic acid alpha-oxidation is thought to occur partly, and pristanic acid beta-oxidation exclusively, in peroxisomes. Accumulation of phytanic acid and pristanic acid is found in blood and tissues of patients affected with generalized peroxisomal disorders.

   

Undecanoylcarnitine

4-(trimethylazaniumyl)-3-(undecanoyloxy)butanoate

C18H35NO4 (329.25659500000006)


Undecanoylcarnitine is an acylcarnitine. More specifically, it is an undecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Undecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine undecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

5-Methyldecanoylcarnitine

3-[(5-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


5-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methyldecanoylcarnitine

3-[(4-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


4-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Methyldecanoylcarnitine

3-[(6-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


6-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-Methyldecanoylcarnitine

3-[(8-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


8-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 8-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 8-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methyldecanoylcarnitine

3-[(7-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


7-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methyldecanoylcarnitine

3-[(3-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


3-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

9-Methyldecanoylcarnitine

3-[(9-methyldecanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


9-Methyldecanoylcarnitine is an acylcarnitine. More specifically, it is an 9-methyldecanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 9-Methyldecanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 9-Methyldecanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Myristoyl Threonine

3-hydroxy-2-tetradecanamidobutanoic acid

C18H35NO4 (329.25659500000006)


N-myristoyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Myristic acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Myristoyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Myristoyl Threonine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

all-cis-7,10,13,16,19-docosapentaenoate

(7Z,10Z,16Z,19Z)-Docosa-7,10,13,16,19-pentaenoic acid

C22H33O2 (329.2480418)


All-cis-7,10,13,16,19-docosapentaenoate, also known as N-3 docosapentaenoic acid or c22:5(omega-3)(1-), is a member of the class of compounds known as very long-chain fatty acids. Very long-chain fatty acids are fatty acids with an aliphatic tail that contains at least 22 carbon atoms. All-cis-7,10,13,16,19-docosapentaenoate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). All-cis-7,10,13,16,19-docosapentaenoate can be found in a number of food items such as grapefruit/pummelo hybrid, chia, capers, and muscadine grape, which makes all-cis-7,10,13,16,19-docosapentaenoate a potential biomarker for the consumption of these food products.

   
   
   
   
   
   
   

Penaresidin B

2S-((11S-hydroxy-13-methyltetradecyl)-4S-(hydroxymethyl)azetidin-3R-ol

C19H39NO3 (329.29297840000004)


   

(2E,4E,9Z)-octadeca-2,4,9-trien-12-ynoic acid isobutylamine

(2E,4E,9Z)-octadeca-2,4,9-trien-12-ynoic acid isobutylamine

C22H35NO (329.27185000000003)


   

3beta-Methylamino-pregn-5-en-20-on|3beta-methylamino-pregn-5-en-20-one|Holaphyllin

3beta-Methylamino-pregn-5-en-20-on|3beta-methylamino-pregn-5-en-20-one|Holaphyllin

C22H35NO (329.27185000000003)


   
   

(+)-7-hydroxyamino-octadecanoic acid methyl ester

(+)-7-hydroxyamino-octadecanoic acid methyl ester

C19H39NO3 (329.29297840000004)


   
   

methylamino-3beta oxo-16 pregnene-17(20) E

methylamino-3beta oxo-16 pregnene-17(20) E

C22H35NO (329.27185000000003)


   

2,3,11a-Trimethyl-2,3,3a,4,5,5a,5b,6,8,9,10,11,11a,11b,12,13-hexadecahydro-1H-2-aza-pentaleno[1,6a-a]phenanthren-9-ol

2,3,11a-Trimethyl-2,3,3a,4,5,5a,5b,6,8,9,10,11,11a,11b,12,13-hexadecahydro-1H-2-aza-pentaleno[1,6a-a]phenanthren-9-ol

C22H35NO (329.27185000000003)


   

Putative (3-hydroxyhexadecanoyl)glycine (aka Commendamide)

Putative (3-hydroxyhexadecanoyl)glycine (aka Commendamide)

C18H35NO4 (329.25659500000006)


   

Penaresidin A

2S-((11S-hydroxy-12-methyltetradecyl)-4S-(hydroxymethyl)azetidin-3R-ol

C19H39NO3 (329.29297840000004)


   

N,N-dimethyl-Safingol

2S-dimethylaminooctadecane-1,3R-diol

C20H43NO2 (329.3293618)


   
   

Dihydroceramide

N-[(2S,3R)-1,3-Dihydroxyoctadecan-2-yl]formamide

C19H39NO3 (329.29297840000004)


   

Palmitoyl Serinol

N-[2-Hydroxy-1-(hydroxymethyl)ethyl]-hexadecanamide

C19H39NO3 (329.29297840000004)


   
   
   

CAR 11:0

3-[(4,8-dimethylnonanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C18H35NO4 (329.25659500000006)


   

NA 19:0;O2

N-(1,3-dihydroxypropan-2-yl)hexadecanamide

C19H39NO3 (329.29297840000004)


   

Commendamide

N-(3-Hydroxyhexadecanoyl) glycine

C18H35NO4 (329.25659500000006)


   

C20 sphinganine

(2S,3R,4E)-2-aminoeicosane-1,3-diol

C20H43NO2 (329.3293618)


A 2-aminoicosane-1,3-diol having (2S,3R)-configuration.

   
   

N-[2-[[2-[[2-[(2-aminoethyl)amino]ethyl]amino]ethyl]amino]ethyl]nonan-1-amide

N-[2-[[2-[[2-[(2-aminoethyl)amino]ethyl]amino]ethyl]amino]ethyl]nonan-1-amide

C17H39N5O (329.3154444)


   

stearylamine acetate

stearylamine acetate

C20H43NO2 (329.3293618)


   

Orciprenaline sulfate

Orciprenaline sulfate

C11H17NO3.1/2H2O4S (329.24471040000003)


Metaproterenol hemisulfate (Orciprenaline hemisulfate) is a direct-acting sympathomimetic and a β2-adrenergic receptor (β2AR) agonist with an IC50 of 68 nM. Metaproterenol hemisulfate also has anti-inflammatory activity[1][2].

   
   

3-[2-carboxyethyl(dodecyl)amino]propanoic acid

3-[2-carboxyethyl(dodecyl)amino]propanoic acid

C18H35NO4 (329.25659500000006)


   

Tetrabutylammonium tetrafluoroborate

Tetrabutylammonium tetrafluoroborate

C16H36BF4N (329.28767740000006)


   

((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol

((1R,3S)-1-amino-3-((R)-6-hexyl-5,6,7,8-tetrahydronaphthalen-2-yl)cyclopentyl)methanol

C22H35NO (329.27185000000003)


   

(3r)-4-(Trimethylammonio)-3-(undecanoyloxy)butanoate

(3r)-4-(Trimethylammonio)-3-(undecanoyloxy)butanoate

C18H35NO4 (329.25659500000006)


   

(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate

(7Z,10Z,13Z,16Z,19Z)-docosapentaenoate

C22H33O2- (329.2480418)


A polyunsaturated fatty acid anion that is the conjugate base of (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

(4Z,7Z,10Z,13Z,16Z)-docosapentaenoate

C22H33O2- (329.2480418)


A polyunsaturated fatty acid anion that is the conjugate base of (4Z,7Z,10Z,13Z,16Z)-docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

(2E,4E,6E,8E,10E)-docosapentaenoate

(2E,4E,6E,8E,10E)-docosapentaenoate

C22H33O2- (329.2480418)


   
   
   
   
   
   
   
   

all-cis-7,10,13,16,19-Docosapentaenoate

all-cis-7,10,13,16,19-Docosapentaenoate

C22H33O2- (329.2480418)


   
   

2-Aminoicosane-1,3-diol

2-Aminoicosane-1,3-diol

C20H43NO2 (329.3293618)


   

(R)-4,8-dimethylnonanoylcarnitine

(R)-4,8-dimethylnonanoylcarnitine

C18H35NO4 (329.25659500000006)


   

N-hexadecanoyl-(2S)-hydroxyglycine

N-hexadecanoyl-(2S)-hydroxyglycine

C18H35NO4 (329.25659500000006)


   
   

N-(1,3-dihydroxyheptadecan-2-yl)acetamide

N-(1,3-dihydroxyheptadecan-2-yl)acetamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxytridecan-2-yl)hexanamide

N-(1,3-dihydroxytridecan-2-yl)hexanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxydodecan-2-yl)heptanamide

N-(1,3-dihydroxydodecan-2-yl)heptanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxypentadecan-2-yl)butanamide

N-(1,3-dihydroxypentadecan-2-yl)butanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxydecan-2-yl)nonanamide

N-(1,3-dihydroxydecan-2-yl)nonanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxyundecan-2-yl)octanamide

N-(1,3-dihydroxyundecan-2-yl)octanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxyoctan-2-yl)undecanamide

N-(1,3-dihydroxyoctan-2-yl)undecanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxytetradecan-2-yl)pentanamide

N-(1,3-dihydroxytetradecan-2-yl)pentanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxynonan-2-yl)decanamide

N-(1,3-dihydroxynonan-2-yl)decanamide

C19H39NO3 (329.29297840000004)


   

N-(1,3-dihydroxyhexadecan-2-yl)propanamide

N-(1,3-dihydroxyhexadecan-2-yl)propanamide

C19H39NO3 (329.29297840000004)


   
   
   
   

Docosapentaenoate

Docosapentaenoate

C22H33O2 (329.2480418)


A polyunsaturated fatty acid anion that is the conjugate base of docosapentaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

Sphingosine (d20:0)

SPH(d20:0)

C20H43NO2 (329.3293618)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   
   

(2e,4e,8e,10e,14e)-n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

(2e,4e,8e,10e,14e)-n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

C22H35NO (329.27185000000003)


   
   

(1r,2r,13s,15r,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,15r,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.28308300000003)


   

(3r)-3-hydroxy-12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

(3r)-3-hydroxy-12-[(2r,5s,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

C18H35NO4 (329.25659500000006)


   

n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

C22H35NO (329.27185000000003)


   

(1r,2r,13r,15s,16s,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13r,15s,16s,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.28308300000003)


   

(1r,2r,13s,15r,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,15r,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.28308300000003)


   

n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

n-(2-methylpropyl)octadeca-2,4,8,10,14-pentaenimidic acid

C22H35NO (329.27185000000003)


   

4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

C22H35NO (329.27185000000003)


   

(1s,2s,10r,11r,13s)-4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

(1s,2s,10r,11r,13s)-4,4-dimethyl-11-(3-methylbut-2-en-1-yl)-12-methylidene-5-oxa-8-azatetracyclo[11.2.1.0¹,¹⁰.0²,⁸]hexadecane

C22H35NO (329.27185000000003)


   

(1r,2r,13s,16s,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,16s,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.28308300000003)


   

(3r)-3-hydroxy-12-[(2r,5r,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

(3r)-3-hydroxy-12-[(2r,5r,6s)-5-hydroxy-6-methylpiperidin-2-yl]dodecanoic acid

C18H35NO4 (329.25659500000006)


   

(2e,4e,9z)-n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

(2e,4e,9z)-n-(2-methylpropyl)octadeca-2,4,9-trien-12-ynimidic acid

C22H35NO (329.27185000000003)


   

3-hydroxy-12-[5-(1-hydroxyethyl)pyrrolidin-2-yl]dodecanoic acid

3-hydroxy-12-[5-(1-hydroxyethyl)pyrrolidin-2-yl]dodecanoic acid

C18H35NO4 (329.25659500000006)


   

(3r)-3-hydroxy-12-[(2s,5s)-5-[(1s)-1-hydroxyethyl]pyrrolidin-2-yl]dodecanoic acid

(3r)-3-hydroxy-12-[(2s,5s)-5-[(1s)-1-hydroxyethyl]pyrrolidin-2-yl]dodecanoic acid

C18H35NO4 (329.25659500000006)


   

(1r,2r,13s,15s,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2r,13s,15s,16r,23r)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.28308300000003)


   

7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.28308300000003)


   

3-hydroxy-12-(5-hydroxy-6-methylpiperidin-2-yl)dodecanoic acid

3-hydroxy-12-(5-hydroxy-6-methylpiperidin-2-yl)dodecanoic acid

C18H35NO4 (329.25659500000006)


   

(1r,2s,13r,15s,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

(1r,2s,13r,15s,16r,23s)-7,9,21-triazahexacyclo[11.9.1.1¹,¹⁵.0²,⁷.0⁹,²³.0¹⁶,²¹]tetracosane

C21H35N3 (329.28308300000003)